Skip to main content
. 2024 Feb 20;6(3):86–93. doi: 10.1253/circrep.CR-23-0098

Table 1.

Demographics and Baseline Characteristics by Country/Region

  Total
(N=3,359)
South Korea
(n=1,887)
Taiwan
(n=983)
Hong Kong
(n=190)
Thailand
(n=299)
Sex, male, n (%) 1,996 (59.4) 1,145 (60.7) 583 (59.3) 112 (58.9) 156 (52.2)
Age, years, mean±SD* 71.7±9.6 70.9±9.0 73.0±10.1 72.9±10.9 71.5±10.3
Weight, kg, mean±SD 65.9±12.4 65.8±11.7 66.3±12.6 64.3±13.3 66.5±15.3
Body mass index, kg/m2, mean±SD** 25.0±3.8 24.8±3.5 25.3±3.9 24.8±4.1 25.4±4.6
eGFR, mL/min/1.73 m2, mean±SD* 62.6±23.8 65.8±23.0 59.1±24.3 55.3±23.3 60.1±24.2
CHA2DS2-VASc, mean±SD* 3.1±1.5 3.0±1.4 3.1±1.4 3.4±1.7 3.5±1.6
Modified HAS-BLED, mean±SD 2.3±1.1 2.2±1.0 2.3±1.1 2.3±1.1 2.5±1.1
Type of AF, n (%)
 Paroxysmal* 1,509 (45.0) 658 (34.9) 607 (62.0) 85 (44.7) 159 (53.2)
 Persistent* 792 (23.6) 542 (28.7) 132 (13.5) 73 (38.4) 45 (15.1)
 Long-standing persistent* 423 (12.6) 319 (16.9) 93 (9.5) 6 (3.2) 5 (1.7)
 Permanent* 631 (18.8) 368 (19.5) 147 (15.0) 26 (13.7) 90 (30.1)
Diabetes mellitus, n (%) 999 (29.7) 534 (28.3) 305 (31.0) 67 (35.3) 93 (31.1)
Hypertension, n (%)* 2,427 (72.3) 1,335 (70.7) 706 (71.8) 135 (71.1) 251 (83.9)
Heart failure, n (%)*,† 418 (12.4) 182 (9.6) 154 (15.7) 21 (11.1) 61 (20.4)
COPD, n (%)** 161 (4.8) 74 (3.9) 64 (6.5) 6 (3.2) 17 (5.7)
Peripheral artery disease, n (%)** 25 (0.7) 6 (0.3) 15 (1.5) 2 (1.1) 2 (0.7)
History of ischemic stroke, n (%)* 507 (15.1) 326 (17.3) 84 (8.5) 42 (22.1) 55 (18.4)
History of major or CRNM bleeding, n (%)* 106 (3.2) 43 (2.3) 32 (3.3) 13 (6.8) 18 (6.0)
History of major bleeding, n (%) 76 (2.3) 37 (2.0) 20 (2.0) 6 (3.2) 13 (4.3)

*P value for difference <0.0001, **P value for difference <0.05. A medical history of heart failure was determined if the patient met one of the following criteria: documented congestive heart failure (CHF) or, if CHF was not reported, documentation of ischemic cardiomyopathy; ejection fraction <40%; frequent dyspnea (≥1/day) without chronic obstructive pulmonary disease and with documented severe valvular heart disease, coronary artery disease post-myocardial infarction, valve replacement, or hypertension treated with ≥3 antihypertensive drugs. AF, atrial fibrillation; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age, Diabetes, Prior Stroke/Transient Ischemic Attack, Vascular disease, and Sex category; COPD, chronic obstructive pulmonary disease; CRNM, clinically relevant nonmajor; eGFR, estimated glomerular filtration rate; HAS-BLED, Hypertension, Abnormal renal and liver function, Stroke, Bleeding history or disposition, Labile international normalized ratio, Elderly, Drugs or alcohol; SD, standard deviation.